Leiden, the Netherlands – February 2nd, 2026 – Medis Medical Imaging, a global leader in AI-powered cardiovascular imaging, today announced the appointment of Kevin DeMoss as VP Commercial QFR – North America of their interventional cardiology portfolio. The appointment supports Medis’ continued growth in North America and the evolving collaborations with clinicians and health systems as cardiovascular care increasingly integrates angiography-based physiology-driven decision-making into routine practice.
Kevin brings more than 20 years of experience across imaging, interventional cardiology, and enterprise health technology. His career has been shaped by close collaboration with clinicians and hospital systems, supporting the responsible adoption of advanced technologies that deliver measurable clinical value while fitting seamlessly into existing workflows.
In his role, Kevin will lead Medis’ North American commercial organization for QFR with a focus on supporting clinical partners as they adopt proven, non-invasive physiological assessment tools. His appointment reflects Medis’ belief that the field of diagnosis and treatment of coronary artery disease is entering a new phase, where trust, usability, and validated performance are essential for sustained clinical adoption.
“What stood out to me about Medis is how approachable the technology is,” said Kevin DeMoss “QFR delivers accurate physiological insights without adding complexity to the cath lab workflow. That level of simplicity, paired with strong clinical validation, is unprecedented in North America, and it creates a meaningful opportunity to support better, more consistent PCI decision-making and optimization.”
Medis’ QFR® technology enables fast, angiography derived assessment of coronary physiology directly from standard angiograms. Designed for intuitive use in high-throughput clinical environments, QFR has been recognized with the Red Dot Award for usability, reflecting Medis’ leadership in translating advanced cardiovascular science into practical clinical tools.
Maya Barley, CEO of Medis Medical Imaging, added: “The North American cardiovascular community has long valued evidence-based innovation. As the field of physiology and CT guided PCI reaches a turning point, ease of use and clinical confidence are becoming just as important as accuracy. Kevin’s experience and clinician-first mindset will help ensure Medis continues to support North American customers with solutions they trust.”
By enabling consistent, physiology-guided assessment during coronary interventions, Medis technologies help clinicians deliver more precise treatment decisions. Ultimately, this supports what matters most: helping more patients receive the best possible PCI, informed by reliable data and streamlined workflows.
About Medis Medical Imaging
For more than 35 years, Medis Medical Imaging has delivered advanced post-processing software for cardiovascular imaging. From MR and CT to X-ray- and angiography-based physiology, Medis equips clinicians with intuitive, scientifically validated tools that enhance diagnostic confidence and streamline workflows. Medis’ portfolio, including QFR®, supports clinicians in delivering high-quality, patient-centered cardiovascular care.
